Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a biotechnology company focused on hereditary angioedema (HAE) and other rare diseases. On this page, you can review BioCryst’s SEC filings alongside AI-generated summaries that help explain complex disclosures in clear language.
Current Reports on Form 8-K are especially important for tracking material events at BioCryst. Recent 8-K filings describe key regulatory milestones, such as U.S. Food and Drug Administration approval of the New Drug Application for an oral pellet formulation of once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric HAE patients aged 2 to <12 years. Other 8-Ks cover quarterly financial results, preliminary revenue updates, and guidance for ORLADEYO net revenue, total revenue including RAPIVAB® (peramivir injection), and non-GAAP operating expenses.
Filings also document strategic transactions that shape BioCryst’s business model. One set of 8-Ks details the Stock Purchase Agreement and subsequent closing of the sale of BioCryst Ireland Limited, which held certain assets and rights related to the European ORLADEYO business, along with associated IP license, supply, brand support, transition services, and trademark license agreements. Another 8-K outlines the Agreement and Plan of Merger under which a BioCryst subsidiary will merge with Astria Therapeutics, Inc., including the cash-and-stock merger consideration, closing conditions, and potential delisting of Astria’s stock.
Governance and compensation developments also appear in BioCryst’s filings. Recent 8-Ks describe the planned retirement of the company’s President and Chief Executive Officer, the appointment of a new President and future CEO, the hiring of a new Chief Financial Officer, and related employment and separation agreements. Additional filings report inducement equity grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Alongside these 8-Ks, investors can use this page to access BioCryst’s periodic reports on Forms 10-K and 10-Q (when available), which provide detailed discussions of risk factors, business strategy, and financial statements. Stock Titan’s AI tools highlight key sections of lengthy documents such as annual reports (10-K), quarterly reports (10-Q), and insider transaction filings (Form 4), helping you quickly understand revenue drivers, major agreements, executive changes, and other disclosures that may affect BCRX.
BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received additional company stock as part of her board compensation. On February 27, 2026, she acquired 528 shares of Common Stock at a price of $8.75 per share through a grant classified as a board retainer in stock rather than cash. After this award, she directly owns 15,382 Common Stock shares. A footnote explains the shares were issued in lieu of 100% of her prorated quarterly cash board member retainer of $4,625, meaning the company paid this portion of her board fees in stock instead of cash.
BIOCRYST PHARMACEUTICALS INC director Jon P. Stonehouse reported several equity transactions. On March 2, 2026, he exercised an employee stock option for 305,995 shares of common stock at an exercise price of $3.22 per share, converting the derivative into common stock.
That same day, he reported a disposition of 305,995 common shares at a weighted average price of $8.64 per share; a footnote states these shares were sold in multiple transactions between $8.54 and $8.81 under a pre-established Rule 10b5-1 trading plan, and the transaction occurred automatically. After this, his direct common stock holdings were 1,323,850 shares.
On February 27, 2026, he also acquired 421 common shares at $8.75 per share, issued in lieu of 50% of a prorated quarterly cash board retainer of $7,375. In addition, there are 40,000 common shares held indirectly in each of two irrevocable trusts, where his wife serves as co-trustee.
MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Vincent Milano received 848 shares of Common Stock as a compensation award. The shares were issued at a reference price of $8.75 per share, bringing his directly held total to 92,067 shares after the transaction.
The footnote explains that these shares were issued in lieu of 50% of his quarterly cash Board member retainer of $11,250 and, effective January 23, 2026, in lieu of 50% of the quarterly cash Board Chair retainer of $20,000. This represents routine equity-based director compensation rather than an open-market purchase or sale.
Frank Steven reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Steven Frank received an equity grant of 1,285 shares of Common Stock on February 27, 2026. The shares were issued in lieu of 100% of his quarterly cash board member retainer of $11,250, reflecting a stock-based compensation choice rather than a market purchase. Following this award, he directly owns 18,903 shares of the company’s common stock.
McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Amy E. McKee reported receiving an award of 642 shares of common stock on February 27, 2026. The shares were issued in lieu of 50% of a quarterly cash board retainer of $11,250, bringing her direct holdings to 42,432 shares.
BioCryst Pharmaceuticals outlines a rare-disease focused strategy centered on hereditary angioedema (HAE) and other orphan conditions. The company’s core product, ORLADEYO, is an oral, once-daily prophylactic for HAE, now approved in multiple markets and expanded to children aged 2 to <12 years via a pellet formulation in the United States.
BioCryst is leveraging this commercial platform with a pipeline that includes navenibart, a Phase 3 anti‑kallikrein antibody for HAE acquired through the Astria Therapeutics merger, BCX17725 for Netherton syndrome, and avoralstat for diabetic macular edema. The report details extensive global partnerships for ORLADEYO, legacy influenza antiviral peramivir (RAPIVAB) supply to the U.S. Strategic National Stockpile, and a broad patent estate protecting kallikrein, antiviral, and other programs, while emphasizing numerous clinical, regulatory, competitive, financing, and operational risks that could impact profitability and growth.
BioCryst Pharmaceuticals reported a major turnaround in 2025, driven by its hereditary angioedema drug ORLADEYO. Total revenues reached $874.8 million, up from $450.7 million, and operating results swung from a small loss to $341.0 million of operating profit.
ORLADEYO net revenue was $601.8 million, up 38% year over year, or 43% excluding the divested European business. On a non-GAAP basis, total revenue was $592.9 million and operating profit $214.2 million, both sharply higher. Net income was $263.9 million, or $1.21 per diluted share, marking the company’s first full-year profitability.
Strategically, BioCryst sold its European ORLADEYO business, received FDA approval for an ORLADEYO oral pellet formulation for children with HAE, and completed the acquisition of Astria Therapeutics, adding Phase 3 antibody navenibart to its HAE portfolio. For 2026, it reaffirmed ORLADEYO revenue guidance of $625–$645 million and total revenue of $635–$660 million, with non-GAAP operating expenses expected between $450–$470 million.
BioCryst Pharmaceuticals, Inc. received an updated ownership report showing that Deerfield-related investment entities and James E. Flynn together beneficially own 14,341,000 shares of its common stock, representing 6.81% of the company as of 12/31/2025.
The shares are held through Deerfield Partners, L.P., with Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Flynn reporting shared power to vote and dispose of these shares, and no sole voting or dispositive power. The filers certify the holdings are not for the purpose of changing or influencing control of BioCryst.
State Street Corporation has filed a Schedule 13G reporting beneficial ownership of 11,073,211 shares of BioCryst Pharmaceuticals Inc. common stock, representing 5.3% of the class as of the event date.
State Street reports no sole voting or dispositive power, with shared voting power over 10,457,690 shares and shared dispositive power over 11,073,211 shares. The holdings are certified as acquired and held in the ordinary course of business, not to change or influence control of BioCryst. Several State Street Global Advisors entities are identified as relevant investment adviser subsidiaries.